Helix BioPharma Corp. (TSX: HBP, OTC: HBPCF, FRANKFURT: HBP0), a clinical-stage oncology company, announced the voting results from its Annual General and Special Meeting of Shareholders held on January 30, 2026. With 81.03% of outstanding shares represented, shareholders voted overwhelmingly in favor of all items of business, demonstrating strong support for the company's strategic direction.
All four director nominees—Jacek Antas, Jerzy Leszczynski, Janusz Grabski, and Malgorzata Laube—were re-elected with over 99.99% of votes in favor each. The appointment of Clearhouse LLP as auditor was also approved with 99.99% support. Notably, a resolution to amend the company's articles to effect a share consolidation of up to five pre-consolidation shares for one post-consolidation share passed with 99.99% of votes cast in favor, authorizing the board to determine the final ratio.
The share consolidation is a significant corporate action that could impact shareholder equity and is often used to meet exchange listing requirements or attract institutional investors. Helix BioPharma, which focuses on hard-to-treat cancers, has a pipeline led by L-DOS47, a clinical-stage antibody-enzyme conjugate targeting CEACAM6-expressing solid tumors. The company's progress in oncology and the strong shareholder endorsement signal confidence in its strategy, though forward-looking statements in the press release caution about risks including clinical trial timelines, financing, and regulatory approvals. Detailed results of the meeting will be filed on SEDAR+ at www.sedarplus.com.
